Skip to main content
Publications
Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, FlieBer-Gorzer E, Gelsinger C, Hanusch U, Ludvik B, Maca T, Schober A, Sock R, Speidl WS, Stulnig TM, Weitgasser R, Zirlik A, Koch M, Wienerroither S, Wolowacz SE, Diamand F, Catapano AL. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wein Klin Wochenschr. 2023 Jul;135(13-14):364-74. doi: 10.1007/s00508-023-02221-4
Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, Chen H, Carrigan G, Rosén K, Szefler S. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol Pract. 2014 Sep;134(3):560-567.e. doi: 10.1016/j.jaci.2014.02.007